Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
77°
Rain Shower
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Scholar Rock
< Previous
1
2
3
Next >
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
August 08, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
July 26, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
July 19, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
July 15, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
July 01, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Announces $205 Million Registered Direct Offering
June 17, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
June 17, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
June 09, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
June 02, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
May 16, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
April 21, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
March 22, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 13, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
February 25, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
January 25, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
January 10, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
November 30, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
November 12, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
November 09, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present at Upcoming Healthcare Conferences
November 02, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
October 03, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
September 30, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
September 28, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress
September 23, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer
August 16, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress
August 10, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference
August 05, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
Scholar Rock Announces Leadership Change
August 03, 2021
From
Scholar Rock
Via
Business Wire
Tickers
SRRK
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.